Pluri Biotech

Big news from Pluri Inc.! 🚀
Our Chairman of the Board, Alejandro Weinstein, is doubling down on his commitment to Pluri’s future with an additional $2.5 million investment-at a 30% premium to the market price!
This investment is a powerful signal of confidence in our team, our technology, and our mission to solve global challenges through cell-based solutions. As CEO Yaky Yanay noted, we are focused on unlocking the immense value within our platform to benefit our shareholders and the world.
Stay tuned as we continue to push the boundaries of biotechnology!

Read more: https://eur05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpluri-biotech.com%2Freleases%2Fpluri-secures-additional-investment-from-chairman-alejandro-weinstein-at-30-premium-to-market-in-a-private-placement%2F&data=05%7C02%7Cnofargl%40Pluri-biotech.com%7C429d557d505843696f4d08de8b464c6e%7Cdddc407fde4d434984cbc328e55f7e8a%7C0%7C0%7C639101331221350281%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=jswpOAeIoo5wlcxJMJTb1sFLgZWRDtvmjw%2F8muCIpCo%3D&reserved=0
$PLUR

Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement - pluri-biotech.com Haifa, Israel – March 26, 2026 – Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of th...

Below is a feature published on Channel 24 highlighting Pluri’s vision for healthy aging and longevity.

As global populations age, physical decline and chronic health challenges are becoming increasingly significant. At Pluri, we are developing scalable cell-based solutions designed to support regeneration, rehabilitation, and natural healing processes — helping improve wellbeing and quality of life over time.

Israeli firm advances 3D cell tech to tackle disease, aging Articles: https://www.i24news.tv/enFacebook: https://www.facebook.com/i24newsEN/Twitter: https://twitter.com/i24NEWS_ENInstagram: https://www.instagram.com/i...

🚀 Pluri Inc CEO Yaky Yanay spoke with Proactive about Pluri’s proprietary cell expansion platform, developed over 20+ years and supported by ~250 patents.

Pluri’s platform is designed for scalable, reproducible, and cost-efficient cell production, enabling the transition of advanced cell-based products from development to commercial-scale manufacturing across therapeutics and FoodTech.

Pluri has also completed Phase I of its collaboration with Resbiomed Technologies OOD through PluriCDMO, with the program now advancing to the next phase.

Pluri showcases cell expansion platform as Resbiomed program advances Pluri Inc CEO Yaky Yanay joined Steve Darling from Proactive to provide deeper insight into the company’s proprietary cell expansion technology and its...

Pluri is entering a new chapter. Under the leadership of Chairman Alejandro Weinstein, the company is transitioning from a research-driven biotech into a commercially focused platform company, unlocking the full value of its patented 3D cell-expansion technology.
By sharpening its focus on high-impact verticals in human health, longevity, and sustainable food production—including cultivated cacao and cell-based coffee—Pluri is building scalable businesses designed to address some of the world’s most urgent challenges while creating meaningful long-term value.

The New "Picasso" Strategy: Pluri Unlocks Hidden Asset Value Through Vertical Focus Pluri Inc. is evolving into a commercial-driven biotech leader under Chairman Alejandro Weinstein, unlocking its 3D cell-expansion platform across longevity and AgTech.